As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers
a unique opportunity to detect the presence of this protein in the human body during life …

Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …

Purpose Positron emission tomography (PET) with amyloid tracers (amy-PET) allows the
quantification of pathological amyloid deposition in the brain tissues, including the white …

The interest of amyloid PET imaging in the diagnosis of Alzh... : Current Opinion in
Neurology The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease …

Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …

The devastating effects of the still incurable Alzheimer's disease (AD) project an ever
increasing shadow of burden on the health care system and society in general. In this …

Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …

Amyloid imaging is currently introduced to the market for clinical use. We will review the
evidence demonstrating that the different amyloid PET ligands that are currently available …

Amyloid-β (Aβ) PET imaging has now been available for over 15 years. The ability to detect
Aβ in vivo has greatly improved the clinical and research landscape of Alzheimer's disease …

Although it afflicts an estimated 26.6 million people worldwide—a figure that is expected to
quadruple by 2050—Alzheimer's disease (AD) has yet to be fully understood etiologically …